 <b>Atlas Medical</b>	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2


**Contents**

1. Amendment Record.
2. General Information.
3. Composition, Information on Active Ingredients.
4. Hazard Information.
5. Fire & Explosion Hazard Data.
6. Accidental release measures.
7. Handling and Storage.
8. Exposure control and personal gear.
9. Physical and chemical properties.
10. Stability and Reactivity Data.
11. Toxicological information.
12. Ecological information.
13. Waste disposal information.
14. Transport information.
15. Regulatory information.
16. Other information.
17. Disclaimer.

**Amendment Record**

Issue Level	Date Issued	Summary of Amendment	Reviewed by
1.1	04.04.2018	General Review	Sondos Shalabi
1.2	03.11.2019	Change address from UK to German address	Sondos Shalabi

PM8.05.07.x.xxxx D.12	Issued for  Date:	Prepared by. QA  Date:	Reviewed by. R&D  Date:	Approved by. QA  Date:	Page 1 of 4
-----------------------	-------------------------	---------------------------------	----------------------------------	---------------------------------	----------------

 <b>Atlas Medical</b>	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2

## 2. General Information.

Trade Names & Synonyms: Bilirubin Direct and Total (DMSO Method).

Chemical Family: In Vitro Diagnostic Test kit (Clinical Chemistry).

Manufacturer: Atlas Medical.

Manufacturer's address: Atlas Medical UG , Ludwig-Erhaed-Ring 3  
15827 Blankenefelde-Mahlow Germany.

Manufacturer's phone: +49(0)33708355030

Email: [info@atlas-medical.com](mailto:info@atlas-medical.com)

## 3. Composition, Information on Active Ingredients.

### ACTIVE INGREDIENTS:

Bilirubin Direct DMSO colorimetric Reagent.  
 Bilirubin Total DMSO colorimetric Reagent.  
 Sodium Nitrate reagent.

Contains no hazardous substances in reportable quantities.

## 4. Hazard Information.

Causes severe burns and Corrosive.

## 5. Fire & Explosion Hazard Data.

**Keep away from sources of ignition.**

**Extinguishing Media:** As appropriate to the environment. Water, foam, powder.

**Special hazards arising from the substance or mixture: Not known.**

**Advice for firefighters:**


**Protective equipment:** Suitable clothing and footwear.

## 6. Accidental release measures.

### 6.1 FIRST-AID MEASURES

**Eyes:** Immediately flush eyes with plenty of water for at least 15 minutes, lifting the upper and lower eyelids. Seek immediate medical advice.

PM8.05.07.x.xxxx D.12	Issued for	Prepared by.	Reviewed by.	Approved by.	Page
	Date:	QA	R&D	QA	2 of 4
		Date:	Date:	Date:	

	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2

**Skin:** Wash skin with plenty of water for at least 15 minutes. Remove contaminated clothing.

Get medical aid if irritation develops or persists.

**Ingestion:** If victim is conscious and alert, wash out mouth with water.

**Inhalation:** Remove from exposure and move to fresh air immediately.

**Notes to Physician:** Treat symptomatically and supportively.

## 6.2 ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures:** Avoid contact with the skin, eyes and clothing. Do not inhale aerosols. Use proper personal protective equipment.

**Environmental precautions:** Do not allow it to enter the drainage system. Avoid pollution of the soil, water supplies and drains.

**Methods and material for containment and cleaning up:** Sweep up material and place into a suitable disposal container. Clean well with water.

## 7. Handling and Storage.

**Handling:** No special indications.

**Storage:** Store in a cool, dry, well-ventilated place in the original container and protect from sunlight. Keep container closed when not in use.

## 8. Exposure control and personal gear.

**Control Parameters:**

Data not available.

**Exposure controls:**

**Technical protective measures:** No special indications.


**Respiratory protection:** If vapours/aerosols formation occurs. Always use a European Standard EN 149 approved respirator when necessary.

**Hand protection:** Wear appropriate protective gloves to prevent skin exposure.

**Eye protection:** Wear appropriate protective eyeglasses or chemical safety goggles as described by European Standard EN166.

**Hygiene measures:** Wash hands before breaks and after work. Do not eat, drink or smoke in the workplace.

PM8.05.07.x.xxxx D.12	Issued for	Prepared by.	Reviewed by.	Approved by.	Page
	Date:	QA	R&D	QA	3 of 4
		Date:	Date:	Date:	

 <b>Atlas Medical</b>	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2

## 9. Physical and chemical properties.

Physical state: R1 – R2 Liquid solution  
 Colour: Colourless. Clear and transparent  
 Odour: Odourless  
 pH value: R1 < 2  
               R2 ~ 6.0  
               R3: 8.35 ± 0.2

Boiling point: -  
 Melting point: -  
 Flash point: -  
 Ignition temperature: -  
 Explosion limits: -  
 Vapour pressure: -  
 Density: -  
 Solubility in water: Yes  
 Viscosity: -

## 10. Stability and Reactivity Data.

**Reactivity:** Not known.

**Chemical Stability:** Stable under normal temperatures and pressures.

**Possibility of hazardous reactions:** Not known.

**Conditions to Avoid:** High temperatures.

**Incompatible Materials:** Not known.

**Hazardous Decomposition Products:** Not known.

## 11. Toxicological information.

Quantitative data on the toxicity of this product are not available. THE FOLLOWING APPLIES TO HYDROCHLORIC ACID:

### 11.1 Acute toxicity


**LC50 inh rat:** 3124 ppm(V)/1 h.

### 11.2 Dangerous health effects

After inhalation: irritations to the respiratory tract

After eyes or skin contact: irritations.

PM8.05.07.x.xxxx D.12	Issued for	Prepared by. QA	Reviewed by. R&D	Approved by. QA	Page 4 of 4
	Date:	Date:	Date:	Date:	

 <b>Atlas Medical</b>	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2

## 12. Ecological information.

Ecological data for this product is not available. THIS APPLIES TO HYDROCHLORIC ACID:

### 12.1 EC50 Test:

Fish Test=25 mg/L; Classification: Toxic

Leuciscus idus=862 mg/L (48h)(1N); Classification: Very toxic.

### 12.2 Receptor medium:

Risk for the water environment= Medium

Risk for the land environment=Medium.

### 12.3 Observations

Has a major acute effect on the water and land environment depending on pH.

It is not bio-accumulable, although it is accumulable in water courses and soils in saline form (Cl-)

### 12.4 Other possible effects:

Generally, its effect is acutely considerable in the dumping area. Its long-term effect is not so considerable if the dumping is not frequent. The treatment is neutralization.

## 13. Waste disposal information.

Accordance with local regulations should be observed.

Handle contaminated packaging in the same way as the substance itself

## 14. Transport information.

This product is not subject to current regulations for transportation of hazardous goods.

## 15. Regulatory information.

SYMBOL

C

Corrosive

R

35

Causes severe burns.

## 16. Other information.


The product is for in-vitro use only.

## 17. Disclaimer.

The information above is believed to be accurate represents the best information currently available to us.

However we make no warranty of merchantability or any other warranty expressed or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purpose. In no way shall the company be liable for any claims, losses or damages of any third party or for lost profits or any special, indirect,

PM8.05.07.x.xxxx D.12	Issued for	Prepared by. QA	Reviewed by. R&D	Approved by. QA	Page 5 of 4
	Date:	Date:	Date:	Date:	

 <b>Atlas Medical</b>	<b>File Title:</b> Product File.	<b>Document Title:</b> Material Safety Data Sheet.	<b>Date Issued</b> 03.11.2019
	<b>Item Title:</b> Bilirubin Direct and Total (DMSO Method).	<b>Item Code:</b> 8.05.07.x.xxxx	<b>Issue Level:</b> 1.2

incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

PM8.05.07.x.xxxx D.12	Issued for  Date:	Prepared by. QA  Date:	Reviewed by. R&D  Date:	Approved by. QA  Date:	Page 6 of 4
-----------------------	-------------------------	---------------------------------	----------------------------------	---------------------------------	----------------